Observational study of inclisiran effectiveness in Moscow healthcare
Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 202...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
«FIRMA «SILICEA» LLC
2023-12-01
|
| Col·lecció: | Российский кардиологический журнал |
| Matèries: | |
| Accés en línia: | https://russjcardiol.elpub.ru/jour/article/view/5687 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|